EBS - Novavax Joins Coronavirus Efforts And Other News: The Good Bad And Ugly Of Biopharma
Novavax Joins Coronavirus Race, Reports Full Year Results
Novavax (NVAX) recently reported receiving a $4 million grant for aiding the development of vaccine for treating the coronavirus disease. The grant has been awarded by the Coalition for Epidemic Preparedness. The news provided a strong impetus to the stock price. The company further reported its fourth quarter and full year results.
Novavax reported its fourth quarter revenue at $8.8 million, up from $6.1 million in revenue it had reported for the corresponding quarter of the previous year. The company received a $7.5 million on